Home > Insider Trading > Filing (0002007919-24-000064)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
2007919	Inhibrx Biosciences Inc.	INBX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1366268	Faiz Jon Kayyem	C/O Inhibrx Biosciences, Inc. 11025 North Torrey Pines Road, Suite 140 La Jolla CA 92037		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-11-19	34,843	$14.23	51,093	No	4	P	Indirect	By Child A
Common Stock	Acquisiton	2024-11-19	34,843	$14.23	51,093	No	4	P	Indirect	By Child B
Common Stock	Acquisiton	2024-11-20	18,750	$14.19	69,843	No	4	P	Indirect	By Child A
Common Stock	Acquisiton	2024-11-20	18,750	$14.19	69,843	No	4	P	Indirect	By Child B

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Child A
No	4	P	Indirect	By Child B
No	4	P	Indirect	By Child A
No	4	P	Indirect	By Child B

Footnotes

The shares were purchased in multiple transactions at prices ranging from $14.09 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
The shares were purchased in multiple transactions at prices ranging from $13.93 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.